Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics following a significant stock decline after the FDA declined to approve its lead drug, reproxalap, for dry eye disease treatment [1][3]. Group 1: Investigation Details - The investigation focuses on whether Aldeyra Therapeutics' executive officers may have violated federal securities laws, potentially allowing for recovery of investor losses [1][4]. - Aldeyra Therapeutics announced on March 17, 2026, that the FDA cited insufficient evidence of efficacy for reproxalap, leading to a stock decline of over 70% in early morning trading on the same day [3]. Group 2: Company Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights, representing both individual and institutional investors in securities class action lawsuits [5]. - The firm has been recognized among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, having recovered approximately $90.725 million for clients in cases where it served as lead or co-lead counsel [6].